Clinical trial
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
NCT06071975 is registered in ClinicalTrials.gov with Apurano Pharmaceuticals GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
- Lead sponsor
- Apurano Pharmaceuticals GmbH
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- November 2, 2023
- Completion date
- December 31, 2024
- Enrollment
- 558 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
chronic pain, chronic pain syndrome, diabetes, diabetic neuropathies, diabetic polyneuropathy, pain, pain syndrome, pain, chronic, peripheral neuralgia, peripheral neuropathy, peripheral neuropathy with type 2 diabetis